Chicago Equity Partners LLC Boosts Stake in Agenus Inc. (AGEN)

Chicago Equity Partners LLC grew its holdings in Agenus Inc. (NASDAQ:AGEN) by 13.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 350,135 shares of the biotechnology company’s stock after acquiring an additional 42,085 shares during the quarter. Chicago Equity Partners LLC owned 0.35% of Agenus worth $1,544,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. OxFORD Asset Management LLP bought a new position in Agenus in the second quarter worth $141,000. Voya Investment Management LLC lifted its position in Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 6,381 shares during the period. American International Group Inc. lifted its position in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 2,984 shares during the period. UBS Asset Management Americas Inc. lifted its position in Agenus by 203.7% in the first quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 34,833 shares during the period. Finally, State of Wisconsin Investment Board bought a new position in Agenus in the second quarter worth $207,000. 39.46% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/11/14/chicago-equity-partners-llc-boosts-stake-in-agenus-inc-agen.html.

Agenus Inc. (NASDAQ AGEN) opened at $3.65 on Tuesday. Agenus Inc. has a twelve month low of $3.20 and a twelve month high of $5.91. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.37). The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $5.91 million. Agenus’s revenue was down 24.4% compared to the same quarter last year. sell-side analysts anticipate that Agenus Inc. will post -1.19 earnings per share for the current fiscal year.

Several research analysts recently commented on AGEN shares. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Wednesday, October 25th. BidaskClub raised Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $7.00 target price on shares of Agenus in a research report on Friday, August 4th. Finally, ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Agenus presently has an average rating of “Hold” and an average target price of $5.81.

In related news, CEO Garo H. Armen acquired 100,000 shares of the business’s stock in a transaction on Monday, October 30th. The stock was bought at an average cost of $3.55 per share, with a total value of $355,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.90% of the stock is currently owned by company insiders.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply